Bruno Lawrence purchased $54K of CLB
Bruno Lawrence (Chairman and CEO) purchased 5,000 shares of Core Laboratories Inc. /DE/ (CLB) at $10.78 on 2026-07-31.
Core Laboratories Inc. /DE/
No enriched coverage for $CLB in the last 7 days.
Bruno Lawrence (Chairman and CEO) purchased 5,000 shares of Core Laboratories Inc. /DE/ (CLB) at $10.78 on 2026-07-31.
Core Laboratories (NYSE:CLB) reported Q2 CY2026 revenue of $124.6 million, down 4.3% year on year, missing analysts’ sales expectations. Non-GAAP profit was $0.11 per share, 26.9% above consensus. Adjusted EBITDA margin was 11.1% and free cash flow was $3.12 million (2.5% margin). The stock fell 4.2% to $9.45 after the release.
Core Laboratories (NYSE:CLB) reported Q2 2026 revenue of $124.6M, up 2% sequentially but down 4% year over year. Operating income was $9.2M, or $9.4M ex-items. GAAP EPS was $0.13, EPS ex-items $0.11. Free cash flow was $3.1M. The company repurchased 214,712 shares for $2.7M and announced a Q3 dividend.
Recent CLB coverage spans earnings, market movers and financial news.
In the last 30 days, CLB insiders filed 1 SEC Form 4 transaction — 1 purchase ($54K) and no sales. The most active reporter was Bruno Lawrence, Chairman and CEO, with 1 filing.
This is a routine insider open-market purchase with no stated 10b5-1 plan, but it is not a fundamental catalyst by itself.
Revenue miss with EPS beat suggests margin support but weaker top-line momentum, likely keeping near-term sentiment cautious.
Results show sequential improvement but continued geopolitical headwinds, with buyback and a declared Q3 dividend adding capital-return signals.
Q2 results show modest revenue softness but strong ex-items improvement, with margins and FCF providing near-term positioning signals.
Move appears driven by oil/geopolitical risk repricing rather than company-specific fundamentals.
alphai scores every news story that mentions CLB with an AI model for sentiment and relevance, and aggregates insider trades from Core Laboratories Inc. /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bruno Lawrence (Chairman and CEO) purchased 5,000 shares of Core Laboratories Inc. /DE/ (CLB) at $10.78 on 2026-07-31.
1 min readCore Laboratories (NYSE:CLB) reported Q2 CY2026 revenue of $124.6 million, down 4.3% year on year, missing analysts’ sales expectations. Non-GAAP profit was $0.11 per share, 26.9% above consensus. Adjusted EBITDA margin was 11.1% and free cash flow was $3.12 million (2.5% margin). The stock fell 4.2% to $9.45 after the release.
5 min readCore Laboratories (NYSE:CLB) reported Q2 2026 revenue of $124.6M, up 2% sequentially but down 4% year over year. Operating income was $9.2M, or $9.4M ex-items. GAAP EPS was $0.13, EPS ex-items $0.11. Free cash flow was $3.1M. The company repurchased 214,712 shares for $2.7M and announced a Q3 dividend.
6 min readCore Laboratories Inc. /DE/ (CLB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2026 RESULTS: • REVENUE OF $124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR • OPERATING INCOME OF $9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND
6 min readCore Laboratories (CLB), Excelerate Energy (EE), and Black Stone Minerals (BSM) fell in afternoon trading as WTI crude dropped 2.2% to about $71.88 and Brent slipped below $77. The article links the pullback to profit-taking after U.S. reports of secondary strikes on Iran and Trump saying the ceasefire is over, while tanker traffic through the Strait of Hormuz reportedly continued.
4 min readAfter President Trump said an Iran ceasefire is over and threatened new strikes, oil prices rose and the energy complex gained. Oilfield services stocks moved higher, including Core Laboratories (+3.6%), Liberty Energy (+4.1%), and Valaris (+3.2%). The article notes WTI near $70 and Brent near $74 and highlights Liberty Energy’s volatility and YTD gain.
4 min readCore Laboratories and Helmerich & Payne shares rose in the afternoon after the U.S. launched self-defense strikes on Iran, with Trump warning Iran would “have to pay the price.” The EIA reported a 7.2 million-barrel weekly crude draw (7th straight) and lower Cushing stocks. Oilfield services firms benefit as upstream drilling/completions increase.
5 min readCore Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, where investors re-elected two Class I directors, Harvey Klingensmith and Curtis Anastasio, to terms running until 2029. Shareholders also ratified KPMG LLP as the independent registered public accountant for 2026 and supported the company's executive compensation philosophy. This indicates broad support for Core Laboratories' governance and leadership structure, despite an AI analyst's "Neutral" rating on the stock due to weak technicals but partially offset by improved leverage and solid margins.
2 min readThis article analyzes the energy sector, which has seen significant gains recently, and recommends one stock to buy while advising against two others. ConocoPhillips (COP) is identified as a strong buy due to its market-beating returns, increasing market share, strong revenue growth, and free cash flow margin. Conversely, SLB (SLB) and Core Laboratories (CLB) are noted as stocks to sell due to high extraction costs, low gross margins, slower revenue growth, and unfavorable valuations.
4 min readIn the current session, Core Laboratories Inc. ( NYSE:CLB ) is trading at $14.95, after a 0.60% drop. Over the past month, the stock decreased by 6.33%, and in the past year, by 26.54%. With performance like this, long-term shareholders are more likely to start looking into the company's ...
2 min read